Harvard Bioscience (HBIO) risk factors, FY2024 10-K

Risks Related to Going Concern

1. 01There is substantial doubt about our ability to continue as a going concern

Risks Related to Our Industry

1. 02The life sciences industry is very competitive
2. 03A portion of our revenues is derived from customers in the pharmaceutical and biotechnology industries and is subject to the risks faced by those industries. Such risks may materially and adversely affect our financial results
3. 04Changes in government regulations may reduce demand for our products, adversely impact our revenues, or increase our expenses

Risks Related to Our Business

1. 05Reductions in customers’ research budgets due to reductions in government funding or delays in government funding may adversely affect our business
2. 06Our business is subject to economic, political and other risks associated with international sales and operations
3. 07Foreign currency exchange rate fluctuations may have a negative impact on our reported earnings
4. 08Failure or inadequacy of our information technology infrastructure or software could adversely affect our day-to-day operations and decision-making processes and have an adverse effect on our performance
5. 09An information security incident, including a cybersecurity breach, could have a negative impact on our business or reputation
6. 10We may be unable to renew leases or enter into new leases on favorable terms or at all
7. 11We may incur additional restructuring costs or not realize the expected benefits of our initiatives to reduce operating expenses in the future
8. 12If we are not able to manage our growth, our operating profits may be adversely impacted
9. 13We may incur a variety of costs in connection with acquisitions we may seek to consummate in the future, and we may never realize the anticipated benefits of our acquisitions due in part to difficulties integrating the businesses, operations and product lines
10. 14If we fail to retain key personnel and hire, train and retain qualified employees, we may not be able to compete effectively, which could result in reduced revenue or increased costs
11. 15Our success will depend partly on our ability to operate without infringing on or misappropriating the intellectual property rights of others
12. 16Third parties may seek to hold us responsible for Harvard Apparatus Regenerative Technologies, Inc.’s (“HRGN”) (formerly known as Biostage, Inc.) liabilities, including liabilities that HRGN has assumed from us

Risks Related to Our Common Stock

1. 17Our stock price has fluctuated in the past and could experience substantial additional declines in the future
2. 18technological innovations by competitors or in competing technologies
3. 19If we raise additional funds through the sale of equity or convertible debt or other equity-linked securities, investors may experience significant dilution of their ownership interest

General Risks

1. 20Epidemics and pandemics have had, and in the future may have, a material adverse impact on our business
2. 21If we incur higher costs as a result of trade policies, treaties, government regulations or tariffs, we may become less profitable
3. 22We may be the subject of lawsuits from counterparties to acquisitions and divestitures, including an acquiring company or its stockholders, an acquired company’s previous stockholders, a divested company’s stockholders or our current stockholders
4. 23Rising commodity and precious metals costs could adversely impact our profitability
5. 24Provisions of Delaware law, or of our charter and bylaws may make a takeover more difficult, which could cause our stock price to decline